
Unity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular ...
Unity Biotechnology announced topline results from its phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. Results from the trial include data from all …